Study: gray-market peptide BPC-157 use jumped 19-fold since 2022
An nference preprint using AI analysis of health records found confirmed BPC-157 users rose from 54 in Q1 2022 to 1,018 in Q1 2026. The unapproved peptide has mainly been studied in animals, and users wait about two months on average before telling their doctor.
- Confirmed BPC-157 users grew from 54 to 1,018 over four years
- Average user age is around 47, with oral use most common
- About half stack it with testosterone, NSAIDs or TB-500
- 96% of those who disclosed use to doctors were white, only 2% African American
Read next
Hardware